BioClinica™ Showcases Clinical Data Management at SCDM Annual Conference
NEWTOWN, Pa.-(Business Wire)-September 29, 2009 - BioClinica, Inc., (NASDAQ: BIOC) a leading global provider of clinical trial services, is helping to advance the discipline of clinical data management and will demonstrate integrated eClinical and imaging data management technology and expertise at the 2009 Society of Clinical Data Management (SCDM) Annual Conference, October 4-6, 2009 in Seattle, WA (Booth # 401). Company experts will share their knowledge of the industry and case studies illustrating the results of improved clinical data management practices. BioClinica is the Diamond Sponsor of the SCDM 2009 Annual Conference.
Processing and managing clinical data is a time-consuming and costly challenge for today’s life science companies that spend billions of dollars every year on drug development and research. As advancements in technology and drug development procedures have increased the volume and complexity of clinical data over the past decade, a greater degree of expertise is required to manage all this information. From study start-up and initiation through data collection and the delivery of final data sets, BioClinica has the knowledge and expertise to deliver maximum results with minimal risk.
“Integrating technology with advanced service delivery eliminates the need for time consuming and costly data reconciliation at the end of a study,” said Mark Weinstein, President and CEO of BioClinica, Inc. “With these capabilities, BioClinica delivers next-generation clinical outsourcing results through improved, integrated, and accelerated clinical trial processes.”
BioClinica supports the SCDM goal of advancing the discipline of clinical data management. Case studies about two BioClinica clients, Pozen, Inc. and Amylin Pharmaceuticals, are finalists for the SCDM Data Driven award honoring the best advancements in clinical data management technology or service.
BioClinica presenters at this conference include:
- Jennifer Price, Senior Director, Clinical Solutions, BioClinica, will co-present a CDISC/CDASH Pre-Conference Tutorial on October 4, 1:00-5:00 p.m. The CDASH initiative is an FDA Critical Path Opportunity that seeks to enable standardized collection of clinical research data at investigative sites. Through standardization of basic data collection elements, efficiencies can be achieved that will result in less confusion across sponsors, investigators, and research sites, and facilitate more efficient monitoring, audit, submission, and review procedures.
- Jonathan Andrus, CCDM, VP, Data and Study Operations, BioClinica, will present during the “Moving Forward – The Future of CDM (Clinical Data Management)” session on October 6 at 3:45-5:00 p.m. Mr. Andrus will specifically address “The Landscape – How Can a CDM Tend It?” The program highlights the challenges clinical data management professionals face as the pharmaceutical/biotech industry strives for leaner, more efficient processes. The speakers in this session will provide three unique perspectives on the future of CDM, and the skill sets that clinical data managers must develop in order to remain competitive in the industry.
BioClinica will also participate in the following industry conferences and tradeshows through November 2009:
ACR/ARHP Scientific Meeting 2009 in Philadelphia, USA, October 16-21:
At the premier event for specialists in the field of rheumatology, BioClinica will highlight its expertise and services to support physicians, health professionals, and scientists advancing the development of new treatments. BioClinica will exhibit at booth #513.
DIA's eClinical Forum in Nice, France, October 19:
Jonathan Andrus, BioClinica's VP of Data and Study Operations will conduct a tutorial on EDC and ePRO at the DIA's eClinical Forum on October 19, 2009 from 9:00a – 12:30p along with Mr. Bryan McDowell of Novartis. Additionally, Mr. Andrus will be presenting on "Mitigating Risk and Improving Data Quality using eClinical Tools" at the same forum in the 2:00p - 3:30p session.
Clinical Trial Supply USA East Coast in Philadelphia, USA, October 19-20:
Ed Tourtellotte, Vice President, Product Innovation at BioClinica, will speak on the positive side-effects of clinical trial supply simulation. This includes kit randomization and packing plans, automatic IVRS specification, enterprise demand forecasting, and program design.
Partnerships with Clinical Trials Europe 2009 in Rotterdam, The Netherlands, November 4-5:
BioClinica will demonstrate integrated solutions to help European life science companies streamline the clinical trial process while reducing costs at the largest gathering of clinical trial outsourcing professionals in Europe.
ISPE 2009 ISPE Annual Meeting in San Diego, USA, November 8-11:
Ed Tourtellotte will present “Simulation Tools - Current Application and Future Evolution”. The ISPE Annual Meeting facilitates the exchange of new ideas and the creation of new relationships among industry leaders to enable ongoing development of industry best practices and solutions.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States and Europe. For more information, please visit www.bioclinica.com.
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
